Biopharmaceutical company Roivant (Nasdaq:ROIV) said on Friday that it will host a live conference call and webcast on Friday, 6 February 2026, to report its financial results for the second quarter ended 31 December 2026, and provide a business update.

Details of the presentation and webcast will be available under 'Events & Presentations' in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

The archived webcast will be available on Roivant's website after the conference call.

Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease.